Clover Biopharmaceuticals, Ltd. (2197.HK)
HKD 0.2
(-3.35%)
HKD 0.2
(-3.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -45.07 Million CNY | 171.88% |
| 2022 | -2.38 Billion CNY | 60.16% |
| 2021 | -2.22 Billion CNY | -562.43% |
| 2020 | -335.04 Million CNY | -2421.73% |
| 2019 | -61.76 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -69.71 Million CNY | 82.99% |
| 2024 Q2 | -69.71 Million CNY | 0.0% |
| 2023 FY | - CNY | 171.88% |
| 2023 Q2 | -871.58 Million CNY | 0.0% |
| 2023 Q1 | -871.58 Million CNY | -36.54% |
| 2023 Q4 | -409.86 Million CNY | 0.0% |
| 2023 Q3 | -409.86 Million CNY | 52.97% |
| 2022 Q2 | -547.26 Million CNY | 0.0% |
| 2022 Q1 | -547.26 Million CNY | 25.63% |
| 2022 FY | - CNY | 60.16% |
| 2022 Q4 | -638.35 Million CNY | 0.0% |
| 2022 Q3 | -638.35 Million CNY | -16.65% |
| 2021 Q2 | -377.32 Million CNY | 0.0% |
| 2021 FY | - CNY | -562.43% |
| 2021 Q4 | -735.88 Million CNY | 0.0% |
| 2021 Q3 | -735.88 Million CNY | -95.03% |
| 2021 Q1 | -377.32 Million CNY | 0.0% |
| 2020 FY | - CNY | -2421.73% |
| 2019 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 149.405% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 109.259% |